News in brief: New treatment approved for mesothelioma; Dairy intake influences asthma risk; Long term results for lumacaftor-ivacaftor

TGA approves improved treatment option for mesothelioma Nivolumab (Opdivo) plus ipilimumab (Yervoy) has been TGA approved for first-line treatment of unresectable malignant pleural mesothelioma. The combination’s registration is based on recent results from the CheckMate -743 trial, which found nivolumab plus ipilimumab improved overall survival compared to standard of care chemotherapy. The international study, published ...

Already a member?

Login to keep reading.

© 2021 the limbic